Categories: All CategoriesCorporateProductsPipelineFinancial Jul 21, 2021Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All EthnicitiesCorporateJul 01, 2021Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 SolutionsCorporateJun 16, 2021Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad GeneticsCorporateJun 04, 2021Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare ConferenceCorporateJun 01, 2021Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle BiosciencesCorporateMay 24, 2021Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 SolutionsCorporateMay 20, 2021 Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health BusinessCorporateMay 05, 2021Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care ConferenceCorporateMay 03, 2021Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to LabcorpCorporateMay 03, 2021Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor DayCorporateApr 27, 2021Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021CorporateApr 27, 2021Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle BiosciencesCorporateMar 29, 2021Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing LeadersCorporateFeb 18, 2021Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth InitiativesCorporateFeb 11, 2021Myriad Genetics to Participate in Multiple Upcoming Health and Technology ConferencesCorporate Next page
